What smart money is saying about Revolution Medicines, Inc.
2 funds in our archive have pitched Revolution Medicines, Inc. — most recently Baron Health Care Fund in June 2026.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Get an email when a fund buys, sells or pitches it
Position history
Between Q4 2025 and Q2 2026, 2 fund letters reported a position in Revolution Medicines, Inc., with 2 buys (opened or added).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 2 | 2 | 0 | 1 |
| Q4 2025 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions · 2 moves
- June 2026
“Top net purchases for the quarter Quarter End Market Cap ($B) Net Amount Purchased ($M) UnitedHealth Group Incorporated 377.5 3.8 Elevance Health, Inc. 84.0 1.9 Revolution Medicines, Inc. 39.8 1.4 Mettler-Toledo International Inc. 25.8 1.4 Sartorius Stedim Biotech S.A. 20.2 0.9 We re-established positions in two previously owned managed care companies, UnitedHealth Group Incorporated and Elevance Health, Inc . Both companies manage diversified portfolios, providing insurance and health care services to Commercial, Exchange, Medicaid and Medicare Advantage members. We believe that the insurance cycle is turning more favorable for these companies, particularly in their Medicare Advantage businesses. After several years of elevated utilization trends, inadequate reimbursement, and regulatory challenges coupled with aggressive pricing to drive share gains, which drove operating margins to depressed levels, UnitedHealth and Elevance have exited unprofitable Medicare Advantage markets and products, right-sized benefits, and are now in the process of rebuilding profitability. We further think that the application of AI will enable them to take a significant bite out of administrative costs as well. Finally, we believe that the earnings power of both companies is well above current levels assuming they can approach their long-term target margins over the next few years. If we further assume a reasonable multiple on future earnings power, we believe there is substantial upside in both stocks. We added to our position in Revolution Medicines, Inc. , a biotechnology company developing medicines to treat cancers driven by rat sarcoma (RAS) mutations.”
Revolution Medicines, Inc. - New positionParnassus Investments Growth Equity FundJune 2026
“We continue to maintain a portfolio balanced between offense and defense. We have taken advantage of ongoing market volatility to selectively participate in secular trends at attractive valuations in AI beneficiaries including hyperscalers, semiconductors and data center and energy infrastructure. Due to the market concentration in mega-cap technology companies, the portfolio’s largest absolute weight continues to be the Information Technology sector, where we have an underweight position relative to the Russell 1000 Growth Index. The portfolio’s largest active weights relative to the Russell 1000 Growth are in Health Care, Communication Services and Materials. The portfolio has no exposure to Energy or Real Estate. We made several position changes during the quarter, selling six positions and adding five new ones. We also adjusted several position sizes in response to the Russell 1000 Growth Index reconstitution. In the Health Care sector, we see compelling long-term idiosyncratic growth opportunities in drug discovery, diagnostics and medical innovation. During the quarter, we added Twist Bioscience, a biotechnology company with a proprietary silicon-based DNA synthesis platform, and Revolution Medicines, developer of a promising new drug for pancreatic cancer.”
Revolution Medicines, Inc.
Fund coverage · 2 theses
- Baron Health Care FundJune 2026
Revolution Medicines develops RAS-targeted cancer drugs, with breakthrough pancreatic data and potential for rapid adoption and large peak sales.
Read the full thesis - Aristotle Large Cap GrowthDecember 2025
Revolution Medicines is an oncology developer with a promising RAS(ON) inhibitor showing strong efficacy and potential accelerated approval, implying significant long-term value.
Read the full thesis
Read every full thesis on Revolution Medicines, Inc.
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→